After the IgG1 mAb antigen-binding fragment binds to the extracellular domain of the HER2 surface of the cancer cell, the NK cell surface of CD16A interacts with the Fc portion of the anti-HER2 molecule coating the cancer cell, inducing NK cell activation. The gene discussed is ERBB2; the disease is cancer.